Crispr Therapeutics AG (NASDAQ:CRSP) has received an average rating of “Buy” from the nineteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $70.86.
A number of equities research analysts have weighed in on the company. Roth Capital raised their price target on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. Goldman Sachs Group increased their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Finally, Chardan Capital reissued a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a report on Monday, November 18th.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,118 shares of company stock worth $3,620,760. Company insiders own 21.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC grew its holdings in shares of Crispr Therapeutics by 5.9% in the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after purchasing an additional 986 shares during the last quarter. Moody Aldrich Partners LLC purchased a new stake in Crispr Therapeutics during the 2nd quarter valued at $1,838,000. Traynor Capital Management Inc. purchased a new stake in Crispr Therapeutics during the 2nd quarter valued at $308,000. Nikko Asset Management Americas Inc. grew its holdings in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. Finally, BNP Paribas Arbitrage SA bought a new stake in Crispr Therapeutics in the 2nd quarter worth $41,000. 49.81% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:CRSP opened at $72.37 on Thursday. The company’s fifty day moving average price is $54.81 and its 200-day moving average price is $47.38. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics has a one year low of $22.22 and a one year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Equities research analysts predict that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Why is the Consumer Price Index (CPI) important?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.